Shopping Cart
- Remove All
Your shopping cart is currently empty
FXIa-IN-15
😃Good
Catalog No. T203612Cas No. 3053222-76-4
FXIa-IN-15 (Compound (S)-10h) is an inhibitor of factor XIa (FXIa) and plasma kallikrein (PKa) with IC50 values of 0.38 nM and 59.2 nM, respectively. It exhibits anticoagulant properties by prolonging the 50% activated partial thromboplastin time (aPTT) with an EC1.5X of 0.55 μM.
FXIa-IN-15
😃Good
Catalog No. T203612Cas No. 3053222-76-4
FXIa-IN-15 (Compound (S)-10h) is an inhibitor of factor XIa (FXIa) and plasma kallikrein (PKa) with IC50 values of 0.38 nM and 59.2 nM, respectively. It exhibits anticoagulant properties by prolonging the 50% activated partial thromboplastin time (aPTT) with an EC1.5X of 0.55 μM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "FXIa-IN-15"
Edoxaban
Lixiana
T2368L480449-70-5
Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with K i s of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3].
- $45
Size
QTY
Betrixaban
PRT054021
T4341330942-05-7
Betrixaban (PRT054021) is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [1]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [3]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [2]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [4].
- $39
Size
QTY
Edoxaban Tosylate Monohydrate
edoxaban tosylate hydrate, DU-176b tosylate Monohydrate, DU-176b monohydrate
T23681229194-11-9
Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.
- $43
Size
QTY
Coumarin
T077591-64-5
Coumarin is a chemical compound/poison found in many plants, notably in high concentration in the tonka bean, woodruff, and bison grass. It has clinical value as the precursor for several anticoagulants, notably warfarin.
- $33
Size
QTY
4-Chlorophenylurea
NSC-12971, NSC12971, NSC 12971
T20454140-38-5
4-Chlorophenylurea (NSC-12971) is a novel orally bioavailable inhibitor of factor Xa.
- $40
Size
QTY
Zifaxaban
TY-602, TY602, TY 602
T292151378266-98-8In house
Zifaxaban (TY-602) is an orally active, competitive and selective inhibitor of factor Xa (FXa) with an IC50 of 11.1 nM for human FXa.Zifaxaban has a very high affinity, more than 10,000-fold higher than that of other serine proteases.Zifaxaban can be used to study arterial and venous thrombosis.
- $350
Size
QTY
Letaxaban
TAK-442
T68092870262-90-1In house
Letaxaban (TAK-442) is a small molecule Xa factor inhibitor that can be used to study polar coronary syndromes and thrombotic blockages.
- $210
Size
QTY
Heparin sodium salt
Cited
Sodium heparinate, Heparin sodium
T65319041-08-1
Heparin sodium is a sulfated polysaccharide, which belongs to the family of glycosaminoglycans. It is utilized as an anticoagulant and interacted with diverse proteins for numerous important biological activities.Heparin sodium salt (Sodium heparinate) significantly inhibits exosome-cell interactions.
- $41
Size
QTY
Cited2-Methoxyphenothiazine
T06421771-18-2
2-Methoxy Phenothiazine is light yellow or light gray solid.
- $29
Size
QTY
Apixaban
BMS-562247-01
T1736503612-47-3
Apixaban (BMS-562247-01) is an orally active anticoagulant that inhibits coagulation factor Xa, directly preventing the conversion of prothrombin to thrombin and the formation of cross-linked fibrin clots.
- $33
Size
QTY
Fidexaban
ZK-807834, PD-200022, CI-1031, CI1031, BX-807834, BX807834
T27318183305-24-0In house
Fidexaban (CI1031) is a novel, potent, selective and orally active factor Xa inhibitor that has demonstrated antithrombotic activity in a variety of assays
- $143
Size
QTY
Gabexate mesylate
FOY
T037256974-61-9
Gabexate mesylate (FOY) is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
- $31
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | FXIa-IN-15 (Compound (S)-10h) is an inhibitor of factor XIa (FXIa) and plasma kallikrein (PKa) with IC50 values of 0.38 nM and 59.2 nM, respectively. It exhibits anticoagulant properties by prolonging the 50% activated partial thromboplastin time (aPTT) with an EC1.5X of 0.55 μM. |
| Molecular Weight | 662.02 |
| Formula | C32H23ClF3N7O4 |
| Cas No. | 3053222-76-4 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy FXIa-IN-15 | purchase FXIa-IN-15 | FXIa-IN-15 cost | order FXIa-IN-15 | FXIa-IN-15 chemical structure | FXIa-IN-15 formula | FXIa-IN-15 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.